Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166133 · ClinicalTrials.gov registry record · NA
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
A NA study, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
NCT07166133: Recruiting NA study, sponsored by W.L.Gore & Associates.
NCT07166133 is a NA study that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 125 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07166133, a NA study, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
Study Summary
A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.
Primary Outcome
Great vessel surgical revascularization procedure is completed, and the endovascular implantation procedure is initiated for the implantation of the TBE Device, without interim death or study discontinuation.
Interventions
- DEVICE GORE® TAG® Thoracic Branch Endoprosthesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2036-03 |
| Phase | NA |
What NCT07166133 shows while recruiting
NCT07166133 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which GORE® TAG® Thoracic Branch Endoprosthesis is the first listed.
NCT07166133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07166133 about?
NCT07166133 is a clinical study titled "GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study". A prospective multi-center post-market study collecting outcomes through at least 5-years and up to 10-years post procedure for subjects treated with the TBE Device in Zone 0/1 as part of routine clinical practice.
What is the current status of trial NCT07166133?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2026-03-02. Estimated completion is 2036-03.
What interventions are being tested in trial NCT07166133?
The interventions under investigation include: GORE® TAG® Thoracic Branch Endoprosthesis (DEVICE).
Who is sponsoring clinical trial NCT07166133?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07166133's enrollment target sits among peer trials
125 753rd of 2000 higher than 1,243 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI